Maia Biotechnology (MAIA) said Tuesday that it has amended a 2021 clinical supply deal with Regeneron (REGN) to cover the expansion of a phase 2 clinical trial evaluating investigational drug THIO in non-small cell lung cancer.
According to the terms of the amended clinical supply agreement, Maia said Regeneron will provide its cancer drug Libtayo to treat all participants in the trial, including the additional patients in the expansion portion of the study.
The expansion part of the trial will further evaluate the efficacy of THIO sequenced with Libtayo in advanced non-small cell lung cancer patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments and chemotherapy, Maia said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.